



Government of  
Saskatchewan

# **Annual Statistical Report 2006-07**

---

## **Saskatchewan Health**

---

Drug Plan and Extended  
Benefits Branch

## *Preface*

This document is a statistical supplement to the Annual Report of Saskatchewan Health for the fiscal year 2006-07. It contains statistical data concerning the programs administered by the Drug Plan and Extended Benefits Branch, including the Drug Plan, Supplementary Health Program, Family Health Benefits and Saskatchewan Aids to Independent Living.

Comments or questions concerning the material in this document may be addressed to:

Drug Plan and Extended Benefits Branch  
Saskatchewan Health  
3475 Albert Street  
Regina, Saskatchewan  
S4S 6X6

---

## *Contents*

Mission Statement .....	2
Eligibility for Coverage .....	3
Highlights for 2006-07 .....	4
<b>The Drug Plan</b> .....	<b>6</b>
Background .....	6
History of Deductibles .....	8
Objectives .....	9
Types of Drug Plan Coverage .....	10
Drugs Covered by the Drug Plan .....	17
Saskatchewan Formulary Process .....	19
Encouraging Appropriate Drug Use.....	23
Pharmacy Claims Processing .....	24
Formulary and EDS Drug Utilization.....	25
2006-07 Utilization Trends .....	39
<b>Supplementary Health &amp; Family Health Benefits</b> .....	<b>44</b>
Background .....	44
Objectives .....	45
Eligible Beneficiaries.....	45
<b>Saskatchewan Aids to Independent Living (SAIL)</b> .....	<b>54</b>
Background .....	54
Eligible Beneficiaries .....	55
Objectives .....	55

## *Tables and Figures*

Figure 1	Prescriptions Dispensed by Age Groups, Eligible and Active Beneficiaries .....	25
Figure 2	Prescriptions Volume by Pharmacologic - Therapeutic Classification .....	34
Table 1	Prescription Use and Drug Plan Payment .....	9
Table 2	Prescription Drug Utilization by Age and Sex of Active Beneficiary .....	26
Table 3	Prescription Drug Utilization by Over/Under 65 .....	28
Table 4	Prescription Cost to Families Approved Under Special Support Program .....	30
Table 5	Prescription Cost to Families Exempt from paying a Deductible .....	31
Table 6	Prescription Cost to Families Under a Deductible Program .....	32
Table 7	Prescriptions by Pharmacologic - Therapeutic Classification .....	33
Table 8	Pharmacies by Location .....	35
Table 9	Pharmacies by Type of Ownership .....	35
Table 10	Drug Acquisition Cost by Manufacturer .....	36
Table 11	Prescription Drug Utilization Trend by Age of Active Beneficiary .....	40
Table 12	Prescription Trend by Pharmacologic - Therapeutic Classification .....	42
Table 13	Prescription Drug Plan Payments Summary .....	43
Table 14	Supplementary Health Program & Family Health Benefits Payments.....	47
Table 15	Caseloads and SAIL Payments .....	55
Table 16	Special Needs Equipment Program – Loans .....	61
Table 17	Orthopaedic Services – Appliances Issued.....	61
Table 18	Orthopaedic Services – Appliances Repaired.....	61

---

# *Drug Plan & Extended Benefits Branch*

The Drug Plan and Extended Benefits Branch was formed on April 1, 1996 by amalgamating the Drug Plan program, the Supplementary Health program, the Saskatchewan Aids to Independent Living program, and the Income testing for Special Care Homes.

## ***MISSION STATEMENT***

Drug Plan and Extended Benefits Branch provides benefits to the eligible Saskatchewan population by:

- promoting optimal, cost-effective drug therapy and extended benefits
- subsidizing qualifying residents and
- facilitating the use of the database

The following kinds of activities contribute to achieving the Mission:

- leading policy development on Drug Plan, SAIL, Supplementary Health and Family Health Benefits related issues
- providing Drug Plan benefits to the eligible Saskatchewan population
- providing non-insured health benefits to residents nominated for Supplementary Health benefits by the Department of Community Resources, and for residents receiving Family Health Benefits
- providing Saskatchewan Aids to Independent Living (SAIL) Program benefits to eligible residents
- administering, on behalf of Health Regions, income-tested resident charges for residents of Special Care Homes
- providing case management services in appropriate areas
- improving program delivery and accountability to the public and the Legislature through trends analysis and annual statistical reports
- providing funds for various initiatives that encourage appropriate use of drugs, e.g. RxFiles Academic Detailing Program
- using the claims paid database for various studies to promote appropriate use of drugs

---

## *Eligibility for Coverage*

### **Drug Plan**

#### **Eligible**

All Saskatchewan residents with valid Saskatchewan Health coverage unless coverage is provided by another federal or provincial government or non-government agency.

#### **Active beneficiaries**

A resident of Saskatchewan who received an eligible prescription.

#### **Not Eligible**

Beneficiaries eligible under the First Nations and Inuit Health Branch of Health Canada, Department of Veteran Affairs, Royal Canadian Mounted Police, Canadian Forces, Workers' Compensation, and inmates of a federal penitentiary.

### **Supplementary Health**

#### **Eligible**

People nominated for coverage by the Department of Community Resources (eg. persons receiving social assistance), inmates of provincial correctional institutions, nominated seniors in special care homes or hospitals whose incomes are below the Saskatchewan Income Plan level.

### **Family Health Benefits**

#### **Eligible**

Families who receive the Saskatchewan Child Benefit and/or the Saskatchewan Employment Supplement.

### **Saskatchewan Aids to Independent Living (SAIL)**

#### **Eligible**

People with long term disabilities or illnesses, which leave them unable to function fully, may receive specialized benefits to help them achieve more independent and active lifestyles.

Saskatchewan residents with valid Saskatchewan Health coverage.

#### **Not Eligible**

Beneficiaries eligible under departments or agencies of the Government of Canada, the Workers' Compensation Board and Saskatchewan Government Insurance.

---

## *Highlights for 2006-07*

### **Drug Plan**

- One in every four families that received a prescription received a financial benefit.
- At June 30, 2006 a total of 899,430 individuals, representing approximately 522,831 family units were eligible to receive Drug Plan benefits.
- A total of 631,225 individual beneficiaries representing 445,363 family units, purchased eligible prescriptions. This represents 70.2% of eligible individuals.
- Tendering of certain high volume interchangeable drug groups helped to keep Formulary drug prices low. Estimated savings for Saskatchewan residents and the Drug Plan in 2006-07 were approximately \$13.25 M.
- Terminally ill patients covered under the Palliative Care Program received 95,238 prescriptions at no charge. The Drug Plan payment for Palliative Care totalled \$4.7 million.
- **The Special Support Program:**
  - helped 68,480 families (64% were senior families).
  - provided benefits in the amount of \$131.0 million.
  - dispensed an average of 41.8 prescriptions to each active beneficiary.
  - dispensed an average of 60.2 prescriptions to each family unit.
  - assisted, on average with 67.5% of the total prescription costs.
- **Active beneficiaries exempt from being income-tested:**
  - helped 54,382 families.
  - provided benefits of \$55.3 million.
  - dispensed an average of 16.1 prescriptions to each active beneficiary.
  - dispensed an average of 20.0 prescriptions to each family unit.
  - assisted, on average with 98.9% of the total prescription costs.
- **Active beneficiaries receiving income supplements and not income-tested:**
  - provided benefits of \$12.5 million.
  - dispensed an average of 9.5 prescriptions to each active beneficiary.
  - dispensed an average of 13.7 prescriptions to each family unit.
  - assisted, on average with 8.2% of the total prescription costs.
- **Drug claims processed for Formulary and Exception Drug Status drugs:**
  - processed 9.6 million prescriptions during April 1/06 to March 31/07.
  - provided benefits in the amount of \$198.8 million.
  - average drug acquisition cost per prescription was \$31.16.
  - average mark-up paid to pharmacies was \$2.99.
  - average dispensing fee paid to pharmacies was \$7.64.

---

## **Supplementary Health**

- The average number of eligible beneficiaries under the program was 39,378.
- Net payments for the program were \$14.97 million during the fiscal 12-month period.
- Program expenditures per eligible beneficiary rose from \$222.52 in 1999-00 to \$380.20 in 2006-07. These figures do not include Formulary Drugs (covered by the Drug Plan).

## **Family Health Benefit Program**

- The average number of eligible beneficiaries under the program in 2006-07 was 58,630 (24,915 adults and 33,715 children). This is a decrease of 3,822 beneficiaries from the previous year. The number of eligible families was 19,295.
- Net payments for the program were \$4.56 million from April 1, 2006 to March 31, 2007. This is an increase of \$118,545 from the previous year. These figures do not include Formulary Drugs (covered by the Drug Plan).

## **Saskatchewan Aids to Independent Living (SAIL)**

- Net payments during the 12-month period were \$3.43 million for Orthopaedic services and \$3.74 million for Special Needs Equipment.
- The SAIL Oxygen program was changed in 1996-97 to provide benefits according to medical criteria. The program cost in 2006-07 was \$8.94 million.
- Net payments for approved beneficiaries were \$8.47 million for non-formulary drugs and \$1.01 million for ostomy supplies.
- A total of 4,218 orthopaedic issues were made in 2006-07, a slight decrease from the previous year. The number of repairs was 3,568 a slight increase from the previous year.
- A total of 23,429 wheelchairs and other special needs equipment aids were loaned to beneficiaries in 2006-07, an increase over the previous year.

---

# *The Drug Plan*

## *Background*

- Enabling legislation for the Drug Plan, The Prescription Drugs Act, was assented to on May 10, 1974.
- The Drug Plan began providing benefits on September 1, 1975. A review process was established to recommend which drugs should be covered under the Drug Plan. The actual acquisition cost plus a dispensing fee comprised the total cost of a Formulary drug. During the first full year, \$14.9 million was paid in benefits; the average prescription cost was \$6.04; and the average consumer share was \$1.96 per prescription.
- On July 1, 1987, a mark-up on the cost of a drug was added. Mark-up was calculated on the acquisition cost before the dispensing fee was added.
- On July 1, 1987, the Drug Plan was changed from a fixed co-payment coverage program to a basic deductible\* and percentage co-payment program. Those residents entitled to special health benefits were exempted.
- On July 1, 1987, Palliative Care coverage was introduced.
- On January 1, 1989, Point of Sale terminals were installed for each pharmacy to submit claims information electronically for adjudication on-line real time.
- On January 1, 1989, eligible drugs purchased anywhere in Canada by all eligible Saskatchewan residents became a benefit.
- On March 8, 1991, beneficiaries in Special Care Homes who previously paid a maximum \$3.95 for each prescription, became part of the deductible plan.
- On July 1, 1991, the coverage policy for drugs in an interchangeable group was changed. The actual acquisition cost of every product in the interchangeable group was now covered only up to lowest listed price in the group.
- In October 1997, implemented a Managed Care Fee for community-based pharmacies that provide monitoring, supervision and other required activities to administer the Methadone Program.
- In December 1997, the Task Force on High Cost Drugs was appointed to determine improvements that would be appropriate to the way government evaluates new pharmaceuticals such as bringing greater transparency to the process; review the implications of providing new drugs in the scope of the Saskatchewan Prescription Drug Plan; and identify actions Saskatchewan should take at the federal, provincial and territorial level, including approaches to a National Pharmacare Program.



- 
- In August 1999, implemented a Trial Prescription Program.
  - In 2000, the Prescription Drug Plan, in partnership with the Saskatoon Health District implemented the RxFiles Academic Detailing Program as an educational program aimed at assisting physicians in selecting the most appropriate and cost-effective drug therapy for their patients. This program became an extension of the Community Drug Utilization Program, established in 1997 as a pilot project in the district.
  - In July 2002, the Income-based program was implemented to replace the \$850 semi-annual deductible.
  - On July 1, 2004 the Maximum Allowable Cost policy was implemented with one group of drugs, the Proton Pump Inhibitors. Under this policy, the price of the most cost effective drugs were used as a guide to set the maximum price the Drug Plan would cover for other similar drugs used to treat the same condition.
  - On September 15, 2004, following a legislative change, the Drug Plan began collecting information on all prescriptions dispensed from community pharmacies, including those that were not benefits of the Drug Plan. This more complete information was an important building block for the Pharmaceutical Information Program (PIP).
  - The Medication Viewer phase of PIP began October 24, 2005 with a pre-production rollout to selected sites to validate production processes. Full production rollout began in March 2006, extending the medication profile viewer to pharmacies, emergency rooms, physician clinics, long-term care and home care facilities as they were equipped and trained. The PIP viewer provides authorized health care professionals with confidential, shared access to patient medication histories to help improve drug therapy for Saskatchewan residents.
  - As of July 1, 2006, the Drug Plan computer system was changed to allow for indefinite EDS coverage on a large number of EDS medications that are used to treat chronic conditions that previously could only be approved for three years at a time. Once a patient meets criteria for one of these chronic medications, coverage is provided for an indefinite period of time and will never need to be renewed. EDS coverage for these patients will only expire when they cease to be a Saskatchewan Health beneficiary.
  - Also on July 1, 2006, the Drug Plan introduced online criteria adjudication of two medications: Actos and Avandia. With the change, patients without current coverage of either Actos or Avandia are automatically approved for coverage when a claim is transmitted and the system finds a Drug Plan benefit alternative on the online profile and/or expired Actos or Avandia coverage.

\* Refers to *History of Deductibles*.

---

## *History of Deductibles:*

- **July 1, 1987**
  - Annual deductible of \$125 (regular family), then a co-payment of 20%.
  - Annual deductible of \$75 (senior family), then a co-payment of 20%.
  - Annual deductible of \$50 (single senior), then a co-payment of 20%.
  
- **March 8, 1991**
  - Annual deductibles as above (1987), then a co-payment of 25%.
  - Residents of Special Care Homes became part of the deductible program.
  
- **May 19, 1992**
  - Semi-annual deductible of \$190 (regular family), then a co-payment of 35% to a \$375 maximum, then 10% co-payment.
  - Single Senior and Senior family deductibles at 1987 level but became semi-annual, with a co-payment of 35% to a \$375 maximum, then 10% co-payment.
  
- **March 19, 1993**
  - Families became eligible for the Special Support program, where families and the Drug Plan shared the cost of prescriptions if the cost for covered drugs exceeded 3.4% of the family income. The family co-payment for each covered prescription was set based on the relation between family income and eligible drug cost.
  - Family Income Plan recipients, Saskatchewan Income Plan recipients, and Guaranteed Income Supplement recipients in special care homes, a semi-annual deductible of \$100 then a co-payment of 35%.
  - All other Guaranteed Income Supplement recipients had a semi-annual deductible of \$200 then a co-payment of 35%.
  - All other family units subject to a deductible and not approved for Special Support had a semi-annual deductible of \$850, then a co-payment of 35%.
  
- **December 1, 1997**
  - The \$50,000 family income cap for the Special Support program was removed.
  
- **August 1, 1998**
  - The Family Health Benefits program was introduced to replace the Family Income Plan. The program provided adults with a semi-annual deductible of \$100 then a co-payment of 35%, and children no charge.
  
- **July 1, 2002**
  - The Income-based program replaced the semi-annual deductible of \$850 that began in 1993.

## **OBJECTIVES**

The Drug Plan has been established to:

- provide coverage to Saskatchewan residents for quality pharmaceutical products of proven therapeutic effectiveness;
- reduce the direct cost of prescription drugs to Saskatchewan residents;
- reduce the cost of drug materials;
- encourage the rational use of prescription drugs.

**Table 1 - Prescription Use & Drug Plan Payment**

Type of Beneficiary	Active Beneficiaries <sup>1</sup>	Number of Prescriptions <sup>2</sup>	%	Total Drug Plan Payment <sup>3</sup>	%
April 2006 - March 2007					
Saskatchewan Assistance Plan Recipients					
-Prescription Charge Subsidized, (Plan One)	16,627	292,767	3.0	\$ 13,655,588	6.9
-Prescription Charge Fully Covered					
Special Drugs for Plan One	1,744	39,696	0.4	1,514,828	0.8
Plan One Dependents to Age 18	6,584	31,816	0.3	988,470	0.5
Plans Two and Three	10,391	367,629	3.8	14,608,879	7.3
Special Beneficiaries					
-Paraplegics	1,274	42,805	0.4	1,759,026	0.9
-Cystic Fibrosis	91	3,111	0.0	694,990	0.3
-Chronic Renal Disease	915	71,485	0.7	5,889,799	3.0
-Others for Certain Drugs <sup>4</sup>	4,828	51,702	0.5	8,671,876	4.4
Family Health Benefits					
-Children	22,517	91,971	1.0	2,843,203	1.4
-Adults	15,769	104,835	1.1	1,196,907	0.6
Palliative Care	2,701	95,238	1.0	4,671,751	2.3
Emergency Assistance	139	708	0.0	26,334	0.0
Special Support	98,552	4,120,965	42.8	131,015,234	65.9
Income Supplement Recipients					
-Saskatchewan Income Plan	4,198	99,897	1.0	1,763,497	0.9
-Guaranteed Income Supplement					
Special Care Home	1,715	68,932	0.7	1,158,376	0.6
Community	17,656	370,802	3.9	5,212,898	2.6
Other Drug Plan Beneficiaries	<u>425,524</u>	<u>3,772,270</u>	39.2	<u>3,172,330</u>	1.6
<b>Total</b>	<b>631,225</b>	<b>9,626,629</b>	<b>100.0</b>	<b>\$ 198,843,985</b>	<b>100.0</b>

1 Active Beneficiaries are more than in other tables as a beneficiary can appear in more than one type in the same year.

2 Refers to Formulary and Exception Drug Status drugs.

3 Drug Plan Payment is the total of the Drug Material Cost and Dispensing fee, less the portion paid by consumers; i.e. deductibles, co-payments, prescription charges and the full cost if not income tested.

4 Prescriptions for certain drugs have been restated to show under Special Beneficiaries to conform with co-payments policies established when approving coverage of new high cost MS drugs.

---

## *Types of Drug Plan Coverage*

### **1. Saskatchewan Assistance Plan Coverage**

Residents receiving benefits through the Saskatchewan Assistance Plan (SAP) are entitled to Drug Plan benefits at a reduced charge, or at no charge depending on their level of coverage. Deductibles are waived for these beneficiaries.

#### **a. Plan One**

Plan One beneficiaries 18 years or older are entitled to receive insulin, oral hypoglycemics, injectable vitamin B12, allergenic extracts, oral contraceptives and some products used in megavitamin therapy at no charge. These beneficiaries pay a reduced charge, to a maximum of \$2.00, for all Formulary and approved Exception Drug Status drugs.

Dependents under 18 years of age are entitled to receive the above benefits at no charge.

#### **b. Plan Two**

Beneficiaries receiving Plan Two coverage are entitled to receive the same benefits as Plan One patients at no charge.

Plan One beneficiaries requiring several Formulary drugs on a regular basis can be considered for “Plan Two” drug coverage. Plan Two drug coverage may be initiated by contacting the Drug Plan. The request can be made by the patient or a health professional (i.e. physician, social worker).

#### **c. Plan Three**

Plan Three beneficiaries are entitled to receive all Formulary drugs and certain non-Formulary drugs at no charge.


The Supplementary Health program covers the cost of certain non-Formulary drugs as well as the cost of megavitamins and allergenic extracts for Plan One and Plan Two beneficiaries.

Plan Three beneficiaries are residents receiving supplementary assistance who live in Special-Care homes licensed under *The Housing and Special-Care Homes Act*, Approved Homes licensed under *The Mental Health Act*, wards of the province and inmates of provincial correctional institutions.


## Saskatchewan Assistance Plan Coverage (Continued)

	<u>2003-04</u>	<u>2004-05</u>	<u>2005-06</u>	<u>2006-07</u>
Number of SAP Active Beneficiaries	38,693	37,565	36,971	35,346

## Saskatchewan Assistance Plan Drug Coverage





## Saskatchewan Assistance Plan Drug Coverage



## 2. Special Beneficiaries

Special Beneficiaries include persons approved for coverage under the paraplegic program, cystic fibrosis program, chronic end-stage renal disease program, and users of certain no charge high cost drugs, depending on their coverage. These beneficiaries may be entitled to receive certain non-Formulary drugs, Exception Drug Status drugs, or all prescribed Formulary drugs at no charge under the Drug Plan.

	<u>2003-04</u>	<u>2004-05</u>	<u>2005-06</u>	<u>2006-07</u>
Number of Active Beneficiaries	4,647	5,632	6,545	7,108





### 3. Palliative Care Coverage

Persons in late stages of terminal illness are entitled to receive at no cost:

- regular Formulary drugs;
- Exception Drug Status drugs where prior approval has been granted;
- most laxatives.


	<u>2003-04</u>	<u>2004-05</u>	<u>2005-06</u>	<u>2006-07</u>
Number of Active Beneficiaries	2,664	2,647	2,789	2,701



---

#### 4. Emergency Assistance

Residents who require immediate treatment with covered prescription drugs and who are unable to cover the cost, may access emergency assistance. An eligible beneficiary may obtain a limited supply of covered prescription drug(s) at a reduced cost. The level of assistance provided will be in accordance with the consumer's ability to pay. Emergency assistance is available on one occasion, after which the beneficiary is then encouraged to apply for Special Support.



#### 5. Income-based program - Special Support Coverage



The Special Support program helps **those families whose drug costs are high in relation to their income**. If the annual drug costs exceed 3.4% of the family adjusted income (income after adjusting for the number of dependents), the family is eligible for Special Support benefits. Residents must apply for the Special Support Program as the Drug Plan does not have access to the required income information.

If a family is eligible for Special Support, the family and the Drug Plan share the prescription cost. The family co-payment is calculated using drug costs and adjusted family income.



## Income-based program - Special Support Coverage (Continued)

	<u>2003-04</u>	<u>2004-05</u>	<u>2005-06</u>	<u>2006-07</u>
Number of Approved Special Support Families	52,854	56,374	63,143	68,480





## 6. Income Supplement Recipients

Single seniors and senior families receiving the Saskatchewan Income Supplement (SIP) or receiving the federal Guaranteed Income Supplement (GIS) and residing in a nursing home have a \$100 semi-annual deductible. Other single seniors and senior families receiving GIS have a \$200 semi-annual deductible. The number of active families continues to decline as more income supplement families begin to incur high drug costs, and apply for Special Support. Other seniors who have higher incomes paid the full cost of their prescriptions up to the regular \$850 semi-annual deductible until June 30, 2002. Starting July 1, 2002, these seniors became eligible for benefits under the income based program.

Note: Families approved for Family Health Benefits are not included in this chart.

	<u>2003-04</u>	<u>2004-05</u>	<u>2005-06</u>	<u>2006-07</u>
Number of Active Families	23,088	22,331	21,649	20,061



---

## Family Health Benefit Program

Effective August 1, 1998, families who received the Saskatchewan Child Benefit, and/or the Saskatchewan Employment Supplement were eligible for the Family Health Benefits Program.

Comprehensive Supplementary Health Benefits became available to children under the age of 18 who qualified (dental, optical, Formulary drugs, medical supplies and appliances and ambulance services).

Partial benefits became available for adults in qualifying families (eye examinations, chiropractic co-payments, \$100 semi-annual Family Drug Plan deductible with a 35% consumer co-payment thereafter).

	2003-04	2004-05	2005-06	2006-07
Number of Active Children Beneficiaries	23,558	23,973	25,043	22,517
Average Number of Prescriptions per Child	4.0	4.0	4.1	4.1
Cost of the Program	\$2.6M	\$2.8M	\$3.1M	\$2.8M

	2003-04	2004-054	2005-06	2006-07
Number of Active Adult Beneficiaries	16,553	17,682	17,584	15,769
Average Number of Prescriptions per Adult	6.4	6.6	6.6	6.6
Cost of the Program	\$1.1 M	\$1.2 M	\$1.2M	\$1.2M

Note: Not included in the above chart is the program cost for Active Adults approved for Special Support. This program cost \$2,707,938 in 2005-06 and \$2,846,595 in 2006-07.

## *Drugs Covered by the Drug Plan*

With the exception of insulin, blood testing agents and urine testing agents, syringes, needles, lancets, and swabs used by patients with diabetes, a prescription is required from a licensed prescriber for all drugs eligible for coverage under the Drug Plan.

## The Formulary

The Drug Plan and Extended Benefits Branch prepares, maintains, and distributes the Saskatchewan Formulary. The Formulary is a listing of therapeutically effective drugs of proven high quality that have been approved for coverage under the Drug Plan.

---

Drugs listed in the Formulary are periodically reviewed and additions and deletions are recommended when necessary. Revised editions of the Formulary are published yearly in July, followed up with updates approximately every quarter. The goal of the Formulary is to list a range and variety of drugs that will enable prescribers to select an effective course of therapy for most patients. The July 2006 Saskatchewan Formulary lists 2,893 Formulary drug products and 735 published Exception Drug Status products.

## **Exception Drug Status**

Certain drugs are reviewed and recommended by the Saskatchewan Formulary Committee for coverage under Exception Drug Status (EDS). All recommendations must be approved by the Minister of Health. The drugs usually fall into one of the following categories:

1. The drug is ordinarily administered only to hospital in-patients but is being administered outside of a hospital because of unusual circumstances.
2. The drug is not ordinarily prescribed or administered in Saskatchewan, but is being prescribed because it is required in the diagnosis or treatment of an illness, disability, or condition rarely found in Saskatchewan.
3. The drug is infrequently used since therapeutic alternatives listed in the Formulary are usually effective, but are contraindicated or found to be ineffective due to the clinical condition of the patient.
4. The drug has been deleted from the Formulary but is required by patients previously stabilized on the drug.
5. The drug has potential for use in other than approved indications.
6. The drug has potential for the development of widespread inappropriate use.
7. The drug is more expensive than listed alternatives and offers an advantage in only a limited number of indications.

Most drugs approved for Exception Drug Status coverage are subject to the same co-payment as the patient's Formulary drugs.

## **Over-the-Counter Products**

Over-the-counter (OTC) products are generally not included as benefits under the Drug Plan.

---

## *Saskatchewan Formulary Process*

### **Product Selection**

The Minister of Health relies on the recommendations of two expert committees; the Drug Quality Assessment Committee, and the Saskatchewan Formulary Committee in order to decide which products will be listed as benefits under the Drug Plan.

The Drug Plan and Extended Benefits Branch provides resources and staff support to the Committees in the review of products for listing in the Saskatchewan Formulary. This support includes forecasting drug costs and preparing use/cost analysis reports.

Saskatchewan is participating in the national Common Drug Review (CDR) which is managed by the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR provides participating federal, provincial and territorial drug benefit plans with a systematic review of the available clinical evidence, a critique of manufacturer-submitted pharmaco-economic studies and a formulary listing recommendation made by the Canadian Expert Drug Advisory Committee (CEDAC).

Note: The Drug Review process described below is in transition and will be changing to reflect the CDR process.

- **Drug Quality Assessment Committee**

The Drug Quality Assessment Committee (DQAC) is appointed by the Minister of Health to:

- evaluate manufacturer submissions for consideration for coverage of new drugs and report its findings to the Saskatchewan Formulary Committee.
- review available manufacturing documentation including clinical documents, reports of scientific studies and published literature.
- evaluate comparative bioavailability studies and/or comparative clinical studies to determine compliance with accepted standards for interchangeability.

---

## **Saskatchewan Formulary Committee**

The Saskatchewan Formulary Committee (SFC), appointed by the Minister of Health, has the following functions:

- recommends to the Minister of Health additions and deletions to the Saskatchewan Formulary. The SFC considers economic information including utilization patterns as well as the clinical assessment of the DQAC.
- provides advice in compiling and maintaining the Saskatchewan Formulary.
- identifies those products which are “interchangeable”. Interchangeable products are different brands of the same drug that are equivalent in therapeutic effectiveness and quality.
- reviews recommendations on new drug products from CEDAC.
- re-evaluates listed products based on new information about use, efficacy and cost.

---

## **Product Interchangeability and Pricing**

One function of the Saskatchewan Formulary Committee is to identify interchangeable drug groups. Interchangeable products are different brands of the same drug with the same strength and dosage form that are equivalent in therapeutic effectiveness and quality. The Formulary lists two types of interchangeable drug groups; Low Cost Alternative, and Standing Offer Contract.

- **Low Cost Alternative**

In order to ensure price stability for the Formulary period, the Drug Plan and Extended Benefits Branch requires drug manufacturers to provide guaranteed maximum prices for the period. The prices constitute the maximum price that the Drug Plan will allow for those products during the effective Formulary period.

Any drug in a Low Cost Alternative interchangeable group can be used to fill a prescription. The drug cost component in the approved prescription price is the actual acquisition cost of the drug up to the lowest price listed in the Formulary within that interchangeable group.

- **Standing Offer Contract (SOC)**

The Drug Plan tenders the drugs in certain interchangeable groups to obtain the lowest possible price. An accepted tender, called SOC, requires the manufacturer to guarantee delivery of the specific drug to pharmacies through approved distributors at the contracted price. In return, the manufacturer's product will be used almost exclusively. This tender process saved an estimated \$13.25M in 2006-07 for beneficiaries and government combined.

Only the accepted tendered drug can be used to fill a prescription in an SOC interchangeable group. If a prescription is ordered as "no substitution" for any brand other than the SOC brand listed, the Drug Plan will cover the actual acquisition cost up to the listed SOC unit price. The difference in acquisition cost between the brand dispensed and the cost covered by the Drug Plan is the responsibility of the consumer.

- **"No Substitution" Prescription Drug Coverage**

It is recognized that extremely rare cases may exist in which a person is not able to use a particular brand of product. In such cases, the physician may request exemption from full payment of incremental cost when a specific brand of drug in an interchangeable category is found to be essential for a particular patient. There is no provision for "blanket" exemptions. Each request must be patient and product specific.

---

- **Maximum Allowable Cost (MAC)**

MAC is a policy to encourage cost-effective prescribing without compromising the health of Saskatchewan residents. Under this policy, the price of the most cost effective drug(s) is used as a guide to set the maximum price the Drug Plan will cover for other similar drugs used to treat the same condition.

Under this policy, residents do not have to switch medications. They have the option of continuing to take the higher-priced prescription drug and paying the difference in cost over the MAC.

The policy was implemented in Saskatchewan on July 1, 2004 with one group of drugs, the Proton Pump Inhibitors (PPIs). These drugs are covered under the Exception Drug Status program and are used to treat various gastrointestinal disorders. The policy was implemented in a staged approach and has resulted in government savings of \$2.5M in 2005-06 and \$2.4M in 2006-07.



---

## *Encouraging Appropriate Drug Use*

The Drug Plan uses a number of activities to encourage appropriate use of drugs:

- Use of the claims processing system to perform various edit and assessment checks.
- Use of Exception Drug Status coverage where drugs are only intended for use in certain circumstances. e.g. products intended for second line use.
- Use of the Maximum Allowable Cost policy to encourage cost effective prescribing.
- Provides funding support for:
  - a) The College of Medicine Drug Evaluation Support - Roving Professorship Program to assist in the drug review process, to provide expert opinions on an ad hoc basis, and to deliver drug information to promote the optimal use of pharmaceuticals in the province.
  - b) The College of Pharmacy & Nutrition Drug Information Services provides a province-wide drug information service for health professionals and consumers.
  - c) The Prescription Review Program operated by the College of Physicians and Surgeons, monitors prescribing for a select panel of prescription drugs with intent to reduce abuse and diversion.
  - d) The RxFiles Academic Detailing Program operated by the Saskatoon Regional Health Authority as an educational program aimed at assisting physicians in selecting the most appropriate and cost-effective drug therapy for their patients.
- The Trial Prescription Program, started as a joint project with the Saskatchewan College of Pharmacists, and later came under the Drug Plan. The pharmacist is encouraged to dispense a seven to ten day supply for the initial prescription of certain drugs, monitor the effect on the patient and if the outcomes are positive, dispense the full prescription as directed by the physician. There is no additional cost to the resident for this service.
- The Pharmaceutical Information Program (PIP) has been developed to provide authorized health care professionals with confidential access to patient medication records. PIP will enhance patient safety by helping physicians and other health care providers select the best medication, avoid drug interactions, and avoid duplications of therapy. The PIP e-prescribing phase began a pre-production implementation in selected sites in spring 2007, with a full rollout to follow in fall 2007. This phase of PIP includes information entered directly by health care providers, such as allergy information, and prescriptions entered electronically by prescribers.

---

## *Pharmacy Claims Processing*

An online computer network transmits prescription information from the pharmacy to the central computer where it is checked against stored data to determine whether it can be approved for payment. Checking includes: is the drug a benefit, does the beneficiary have health coverage and the type, is the quantity dispensed within appropriate levels, is the number of prescriptions for the beneficiary within limits, is the prescription a duplicate or possible duplicate of another dispensed prescription, is the prescriber authorized, are the unit costs within limits. The prescription claim is adjudicated and cost information is then transmitted back to the pharmacy, detailing the consumer share and Drug Plan share.

- **Pharmacy Reimbursements**

At March 31, 2007, there were 374 pharmacies providing Drug Plan eligible services.

According to the agreement between Saskatchewan Health and pharmacy proprietors, the prescription cost is calculated by adding the acquisition cost of the drug material, the submitted mark-up and dispensing fee (up to a maximum).

The maximum dispensing fee was increased to \$8.46 on October 1, 2006. From December 1, 2005 to September 30, 2006, the dispensing fee was \$8.21. From September 1, 2003 to November 30, 2005, the maximum dispensing fee was \$7.97. The maximum mark-up allowance calculated on the prescription drug cost is: 30% for drug cost up to \$6.30, 15% for drug cost between \$6.31 and \$15.80, 10% for drug cost of \$15.81 to \$200.00, and a maximum mark-up of \$20.00 for drug cost over \$200.00. The tiered mark-up and dispensing fee do not apply for diabetic supplies.

For urine-testing agents the pharmacy receives acquisition cost along with the mark-up and a 50% mark-up in place of the dispensing fee. For insulin, the pharmacy receives acquisition cost plus a negotiated mark-up. For diabetic supplies, (syringes, needles, lancets and swabs) the pharmacy receives actual acquisition cost plus a mark-up not to exceed 50%.

- **Prescription Quantities**

The Drug Plan places no limitation on the quantities of drugs that may be prescribed. Prescribers shall exercise their professional judgment in determining the course and duration of treatment for their patients. However, in most cases, the Drug Plan will not pay benefits or credit deductibles for more than a 3 month supply of a drug at one time.

The pharmacist may charge one dispensing fee for each prescription for most drugs listed in the Formulary. The pharmacist is entitled to charge a dispensing fee for each 34 day supply, however, the Pharmacy Agreement does not prohibit the pharmacist from dispensing more than a 34 day supply for one fee. The Pharmacy Agreement also contains a list of 2 month and 100 day maintenance drugs. Once a patient's therapy is stable, prescribing and dispensing of these drugs should be in quantities of 2 months or 100 days, unless there are unusual circumstances that require different quantities.

---

## *Formulary and EDS Drug Utilization 2006-07*

At June 30, 2006, a total of 899,430 individuals, representing approximately 522,831 family units were eligible to receive Drug Plan benefits.


A total of 631,225 individual beneficiaries representing 445,363 family units, purchased eligible prescriptions. This represents 70.2% of eligible individuals.

### **1. Overall 2006-07 Utilization**

Figure 1 compares active Drug Plan beneficiaries to the eligible population and shows the percentage of total prescriptions dispensed to each age group. This shows that the 65+ age group is 16.1% of the eligible population, represents 21.4% of Drug Plan active beneficiaries, and receive 47.1% of all prescriptions.

Table 2 presents prescription drug utilization by age and sex of the beneficiary. It also shows that drug utilization increases with age, with the larger increases beginning at age 45.

**Figure 1**  
**Prescriptions Dispensed by Age Groups, Eligible and Active Beneficiaries**



**Table 2**  
**Prescription Drug Utilization by Age and Sex of Active Beneficiary**

Age of Consumer <sup>1</sup>	Active Beneficiaries	Number of Prescriptions <sup>2</sup>	Drug Material Cost <sup>3</sup>	Dispensing Fee <sup>4</sup>	Total Drug Plan Payment <sup>5</sup>
April 2006 - March 2007 (as submitted for all prescriptions to all beneficiaries)					
<b>Male</b>					
0 - 4	17,471	59,897	\$ 780,519	\$ 467,891	\$ 498,408
5 - 14	28,369	112,554	3,101,504	858,427	1,992,972
15 - 24	33,143	146,084	4,968,985	1,093,262	2,950,334
25 - 34	27,194	167,499	6,586,969	1,281,539	4,275,986
35 - 44	32,679	304,158	13,252,830	2,330,385	8,380,467
45 - 54	44,788	623,993	25,950,434	4,787,875	13,236,371
55 - 64	38,035	813,417	31,644,485	6,125,772	15,776,812
65 - 74	28,502	823,673	29,076,526	6,142,373	17,356,589
75 - 84	21,219	732,395	23,124,700	5,564,034	15,267,433
85 and over	6,817	248,916	6,632,901	1,956,588	4,805,611
<b>Male Total</b>	<b>278,217</b>	<b>4,032,586</b>	<b>\$ 145,119,854</b>	<b>\$ 30,608,145</b>	<b>\$ 84,540,984</b>
<b>Female</b>					
0 - 4	15,914	49,498	\$ 635,164	\$ 387,949	\$ 451,560
5 - 14	27,452	92,518	2,440,751	707,987	1,680,364
15 - 24	50,494	300,676	8,561,166	2,305,585	3,593,502
25 - 34	42,960	333,920	11,146,964	2,560,678	5,591,924
35 - 44	43,469	434,306	17,138,689	3,316,440	9,893,530
45 - 54	52,823	762,202	30,384,399	5,818,200	16,709,549
55 - 64	41,288	890,056	32,002,202	6,731,561	18,323,207
65 - 74	31,980	924,873	30,765,535	6,972,578	20,216,924
75 - 84	29,219	1,076,519	32,214,491	8,330,536	22,943,448
85 and over	17,409	729,475	18,381,609	5,791,932	14,898,994
<b>Female Total</b>	<b>353,008</b>	<b>5,594,043</b>	<b>\$ 183,670,972</b>	<b>\$ 42,923,446</b>	<b>\$ 114,303,001</b>
<b>Both Sexes</b>					
0 - 4	33,385	109,395	\$ 1,415,683	\$ 855,840	\$ 949,968
5 - 14	55,821	205,072	5,542,256	1,566,414	3,673,336
15 - 24	83,637	446,760	13,530,151	3,398,847	6,543,836
25 - 34	70,154	501,419	17,733,933	3,842,217	9,867,910
35 - 44	76,148	738,464	30,391,519	5,646,825	18,273,998
45 - 54	97,611	1,386,195	56,334,833	10,606,074	29,945,920
55 - 64	79,323	1,703,473	63,646,687	12,857,333	34,100,020
65 - 74	60,482	1,748,546	59,842,061	13,114,951	37,573,513
75 - 84	50,438	1,808,914	55,339,192	13,894,569	38,210,881
85 and over	24,226	978,391	25,014,511	7,748,520	19,704,605
<b>Grand Total</b>	<b>631,225</b>	<b>9,626,629</b>	<b>\$ 328,790,826</b>	<b>\$ 73,531,592</b>	<b>\$ 198,843,985</b>

1 Age of beneficiary as at March 31, 2007.

2 Refers to Formulary and Exception Drug Status drugs.

3 Includes mark-up on drug acquisition cost.

4 The Dispensing fee charged by pharmacy for the prescriptions dispensed.

5 Drug Plan Payment is the total of the Drug Material Cost and Dispensing fee; less portion paid by consumers; such as deductibles, co-payments, prescription charges and the full cost if not income tested.

---

## **2. 2006-07 Utilization by Type of Beneficiary**

Drug Plan benefits are directed at families with low incomes, families with high drug costs and those with a combination of the two. Table 3 summarizes the beneficiaries into five main groups:

1. beneficiaries approved for an Income-based Special Support co-payment;
2. beneficiaries exempt from paying a co-payment, some of which are on Saskatchewan Assistance Plan (SAP), Saskatchewan Aids to Independent Living (SAIL) beneficiaries, palliative care, or those who receive certain high cost drugs grandfathered at 100%;
3. beneficiaries approved for Family Health Benefits;
4. beneficiaries approved for Income Supplement under Saskatchewan Income Plan (SIP), and Guaranteed Income Supplement (GIS);
5. other Drug Plan beneficiaries.

**Table 3**  
**Prescription Drug Utilization by Over/Under 65**

April 2006 - March 2007

Type of Beneficiary	Active Beneficiaries	Number of Prescriptions <sup>1</sup>	Payment Patient Paid	Average Cost to Patient	Drug Plan Payment <sup>2</sup>	Average Cost to Drug Plan
<b>Beneficiaries approved under Income-based Special Support Program</b>						
Under 65	41,560	1,321,328	\$ 26,867,049	\$ 646.46	\$ 54,386,516	\$ 1,308.63
65 and over	<u>56,992</u>	<u>2,799,637</u>	<u>36,091,086</u>	633.27	<u>76,628,718</u>	1,344.55
Sub-Total	<u>98,552</u>	<u>4,120,965</u>	<u>\$ 62,958,135</u>	\$ 638.83	<u>\$ 131,015,234</u>	\$ 1,329.40
<b>Beneficiaries exempt from paying a Deductible (e.g. SAP, SAIL, Palliative Care)</b>						
Under 65	40,103	803,239	\$ 582,585	\$ 14.53	\$ 42,436,795	\$ 1,058.20
65 and over	<u>5,052</u>	<u>193,010</u>	<u>18,631</u>	3.69	<u>10,018,412</u>	1,983.06
Sub-Total	<u>45,155</u>	<u>996,249</u>	<u>\$ 601,216</u>	\$ 13.31	<u>\$ 52,455,207</u>	\$ 1,161.67
<b>Beneficiaries receiving Family Health Benefits (excludes prescriptions under Special Support)</b>						
Under 65	38,241	195,960	\$ 2,138,148	\$ 55.91	\$ 4,027,425	\$ 105.32
65 and over	<u>45</u>	<u>846</u>	<u>13,100</u>	291.11	<u>12,685</u>	281.89
Sub-Total	<u>38,286</u>	<u>196,806</u>	<u>\$ 2,151,248</u>	\$ 56.19	<u>\$ 4,040,110</u>	\$ 105.52
<b>Beneficiaries receiving Income Supplements (SIP &amp; GIS not covered under Special Support)</b>						
Under 65	1,718	25,352	\$ 517,525	\$ 301.24	\$ 367,827	\$ 214.10
65 and over	<u>21,851</u>	<u>514,279</u>	<u>9,083,344</u>	415.69	<u>7,766,944</u>	355.45
Sub-Total	<u>23,569</u>	<u>539,631</u>	<u>\$ 9,600,869</u>	\$ 407.35	<u>\$ 8,134,771</u>	\$ 345.15
<b>Other Drug Plan Beneficiaries (families whose Income Supplement coverage or special support benefits ended by fiscal year end)</b>						
Under 65	374,458	2,744,943	\$ 93,908,322	\$ 250.78	\$ 2,136,669	\$ 5.71
65 and over	<u>51,205</u>	<u>1,028,035</u>	<u>34,258,643</u>	669.05	<u>1,061,995</u>	20.74
Sub-Total	<u>425,663</u>	<u>3,772,978</u>	<u>\$ 128,166,965</u>	\$ 301.10	<u>\$ 3,198,664</u>	\$ 7.51
<b>Grand Total</b>	<b>631,225</b>	<b>9,626,629</b>	<b>\$ 203,478,432</b>		<b>\$ 198,843,985</b>	

1 Refers to Formulary and Exception Drug Status drugs.

2 Drug Plan Payment is the total of the Drug Material Cost and Dispensing fee, less the portion paid by consumers; such as deductibles, co-payments, prescription charges and the full cost if not income tested.

---

### 3. 2006-07 Utilization by Families

Tables 4, 5, and 6 show the breakdown of prescription utilization, family cost, and government cost for all families using one or more prescriptions in the fiscal year by three categories of families:

1. Families that applied for Special Support and were granted a reduced co-payment because their annual drug costs exceeded 3.4% of their annual family income;
2. Families exempt from a co-payment program. (e.g. some Saskatchewan Assistance Plan families, SAIL beneficiaries, Palliative Care, children of families approved for Family Health Benefits);
3. Families Receiving Income Supplements, and not income-tested. Families included in this table are:
  - Those that have a \$100 semi-annual deductible because they are adults of families approved for Family Health Benefits (FHB), single seniors and senior families receiving the Saskatchewan Income Supplement (SIP), or those receiving the federal Guaranteed Income Supplement (GIS) and residing in a nursing home.
  - Those that have a \$200 semi-annual deductible because they receive GIS.
  - Those that paid the full cost of prescriptions who did not apply for the income-based Special Support Program.

In 'Families Approved under the Special Support Program' (Table 4), 68,480 families who had high drug costs in relation to their income received \$131 million in benefits, which equals an average payment of \$1,913.19 per family, an increase of 5.0% over the previous year.

In 'Prescription Cost to Families Exempt from being Income Tested' (Table 5), the average payment on behalf of each active family was \$1,016.85, an increase of 5.0% over the previous year.

In 'Prescription Cost to Families Receiving Income Supplements, and Not Income Tested' (Table 6), the average payment on behalf of each active family was \$38.85.

**Table 4****Prescription Cost to Families Approved Under Special Support Program**

April 2006 - March 2007

Cost to Family Unit	Number of Family Units	Number of Prescriptions <sup>1</sup>	Drug Material Cost <sup>2</sup>	Approved Prescription Cost	Net Family Payments <sup>3</sup>	Total Drug Plan Payment <sup>4</sup>
\$ 00.01 - 25.00	1,440	15,731	\$ 530,483	\$ 649,989	\$ 6,290	\$ 643,699
25.01 - 50.00	756	15,358	575,008	690,174	28,015	662,159
50.01 - 75.00	663	15,255	605,236	721,749	41,156	680,592
75.01 - 100.00	584	12,826	482,607	579,310	50,960	528,349
100.01 - 125.00	589	13,648	561,295	667,370	66,047	601,323
125.01 - 150.00	592	16,961	689,421	820,895	81,444	739,451
150.01 - 175.00	646	17,776	780,177	913,912	104,992	808,920
175.01 - 200.00	640	19,791	875,353	1,027,405	120,038	907,367
200.01 - 250.00	1,479	49,738	2,069,654	2,448,363	332,924	2,115,439
250.01 - 300.00	1,829	69,835	2,534,093	3,069,643	504,655	2,564,988
300.01 - 350.00	2,289	99,559	3,467,133	4,241,278	745,313	3,495,965
350.01 - 400.00	3,144	150,187	5,045,191	6,212,448	1,181,848	5,030,600
400.01 - 450.00	3,738	192,758	6,205,101	7,699,030	1,589,247	6,109,783
450.01 - 500.00	3,727	205,458	6,542,314	8,147,757	1,768,828	6,378,929
500.01 - 600.00	6,282	356,795	12,055,290	14,817,987	3,448,805	11,369,182
600.01 - 725.00	6,409	388,191	13,363,941	16,363,551	4,233,295	12,130,256
725.01 - 850.00	5,336	354,363	12,348,353	15,074,896	4,189,647	10,885,249
850.01 - 1000.00	5,300	372,297	13,751,379	16,590,084	4,891,963	11,698,121
1000.01 - 1250.00	6,538	461,183	17,764,791	21,266,630	7,306,337	13,960,293
1250.01 - and over	16,499	1,293,255	62,343,484	71,970,899	32,266,331	39,704,569
All	68,480	4,120,965	\$ 162,590,303	\$ 193,973,368	\$ 62,958,135	\$ 131,015,234

1 Refers to Formulary and Exception Drug Status drugs.

2 Includes mark-up on drug acquisition cost.

3 Net Family Payments is the total cost paid by families granted a reduced co-payment.

4 Drug Plan Payment is the total of the Drug Material Cost and Dispensing fee; less portion paid by consumers; such as deductibles, co-payments, prescription charges and the full cost if not income tested.



**Table 5**  
**Prescription Cost to Families Exempt from being Income-tested**

April 2006 - March 2007

Cost to Family Unit	Number of Family Units	Number of Prescriptions <sup>1</sup>	Drug Material Cost <sup>2</sup>	Approved Prescription Cost	Net Family Payments <sup>3</sup>	Total Drug Plan Payment <sup>4</sup>
\$ NIL	36,638	680,826	\$ 32,578,840	\$ 37,956,781	\$ -	\$ 37,956,781
00.01 - 25.00	10,921	94,482	2,478,182	3,232,619	95,595	3,137,024
25.01 - 50.00	2,943	73,759	2,843,206	3,435,007	107,340	3,327,667
50.01 - 75.00	1,430	54,625	2,207,054	2,658,155	88,848	2,569,307
75.01 - 100.00	992	51,927	1,976,293	2,398,271	85,928	2,312,343
100.01 - 125.00	555	37,899	1,459,733	1,778,734	62,110	1,716,624
125.01 - 150.00	335	26,918	1,115,223	1,338,503	45,996	1,292,507
150.01 - 175.00	205	19,581	718,878	875,046	33,213	841,832
175.01 - 200.00	124	13,477	528,322	638,973	23,343	615,630
200.01 - 250.00	136	17,774	677,815	825,771	30,167	795,604
250.01 - 300.00	50	8,076	311,348	374,620	13,720	360,900
300.01 - 350.00	23	4,313	142,900	175,641	7,479	168,161
350.01 and over	30	4,563	175,390	211,820	7,790	204,030
All	54,382	1,088,220	\$ 47,213,185	\$ 55,899,939	\$ 601,529	\$ 55,298,410

1 Refers to Formulary and Exception Drug Status drugs.

2 Includes mark-up on drug acquisition cost.

3 Refers to the maximum \$2 per prescription charge paid by the family.

4 Drug Plan Payment is the total of the Drug Material Cost and Dispensing fee; less portion paid by consumers; such as deductibles, co-payments, prescription charges and the full cost if not income tested.

**Table 6****Prescription Cost to Families Receiving Income Supplements, and Not Income-Tested <sup>5</sup>**

April 2006 - March 2007

Cost to Family Unit	Number of Family Units	Number of Prescriptions <sup>1</sup>	Drug Material Cost <sup>2</sup>	Approved Prescription Cost	Net Family Payments <sup>3</sup>	Total Drug Plan Payment <sup>4</sup>
\$ 00.01 - 25.00	40,638	43,858	\$ 257,363	\$ 594,136	\$ 573,973	\$ 20,163
25.01 - 50.00	34,428	73,086	711,989	1,277,477	1,252,715	24,761
50.01 - 75.00	22,694	74,143	865,409	1,436,802	1,401,258	35,545
75.01 - 100.00	16,927	72,386	951,031	1,507,079	1,468,669	38,410
100.01 - 125.00	14,184	72,529	1,080,432	1,635,931	1,588,730	47,201
125.01 - 150.00	11,497	70,716	1,098,627	1,637,171	1,578,064	59,107
150.01 - 175.00	10,392	71,480	1,201,036	1,745,368	1,685,303	60,065
175.01 - 200.00	9,605	74,422	1,316,840	1,882,709	1,800,078	82,632
200.01 - 250.00	18,296	160,551	3,088,370	4,305,203	4,112,841	192,363
250.01 - 300.00	15,448	160,107	3,270,557	4,485,624	4,232,985	252,639
300.01 - 350.00	11,815	146,834	3,016,560	4,132,467	3,828,644	303,823
350.01 - 400.00	9,985	138,640	3,031,222	4,082,885	3,738,620	344,265
400.01 - 450.00	8,851	137,368	3,122,282	4,165,784	3,756,819	408,966
450.01 - 500.00	7,872	134,446	3,166,832	4,187,823	3,734,608	453,215
500.01 - 600.00	13,623	259,678	6,435,877	8,410,826	7,470,472	940,355
600.01 - 725.00	14,041	312,299	8,206,494	10,578,840	9,273,072	1,305,768
725.01 - 850.00	10,854	279,032	7,710,465	9,827,484	8,519,713	1,307,772
850.01 - 1000.00	10,246	296,431	8,515,369	10,764,415	9,447,776	1,316,641
1000.01 - 1250.00	12,539	420,513	12,610,581	15,797,287	14,000,561	1,796,726
1250.01 - and over	28,566	1,418,925	49,329,879	59,993,796	56,453,867	3,539,928
All	322,501	4,417,444	\$ 118,987,215	\$ 152,449,109	\$ 139,918,768	\$ 12,530,342

1 Refers to Formulary and Exception Drug Status drugs.

2 Includes mark-up on drug acquisition cost.

3 Net Family Payments is the full cost of prescriptions for those families who are not income-tested, and is the net cost to an Income Supplement family for the total of the deductible and the family co-payment once the deductible has been met.

4 Drug Plan Payment is the total of the Drug Material Cost and Dispensing fee; less portion paid by consumers; such as deductibles, co-payments, prescription charges and the full cost if not income tested.

5 Includes beneficiaries covered under the semi-annual Income Supplement deductibles, and those families who are not income-tested to receive benefits

#### 4. 2006-07 Utilization by Pharmacologic - Therapeutic Classification

Table 7 shows prescription volume and Drug Plan expenditures by Pharmacologic - Therapeutic Classification. Four categories; Central Nervous System (CNS) Drugs, Cardiovascular Drugs, Hormones and Substitutes and Anti-Infectives, accounted for 69.0% of all prescriptions and 57.8% of the Drug Plan payment.

**Table 7**  
**Prescriptions by Pharmacologic - Therapeutic Classification**

Pharmacologic - Therapeutic Classification <sup>1</sup>	Number of Prescriptions <sup>2</sup>	Drug Material Cost <sup>3</sup>	Total Drug Plan Payment
April 2006 - March 2007			
As submitted for all beneficiaries			
8:00 Anti-Infectives	668,222	\$ 12,166,138	\$ 6,988,787
10:00 Antineoplastic agents	826	129,123	107,138
12:00 Autonomic Drugs	305,341	10,818,255	7,169,109
20:00 Blood Formation and Coagulation	225,587	10,361,024	8,238,917
24:00 Cardiovascular Drugs	2,910,071	108,514,537	52,050,327
28:00 Central Nervous System Drugs	1,897,562	60,708,458	40,924,782
36:00 Diagnostic Agents	133,490	10,399,304	5,914,053
40:00 Electrolytic, Caloric, and Water Balance	529,127	2,664,773	3,371,085
48:00 Cough Preparations	290	155,998	154,668
52:00 Eye, Ear, Nose and Throat Preparations	298,745	7,950,083	3,277,394
56:00 Gastrointestinal Drugs	502,811	19,678,036	12,291,612
60:00 Gold Compounds	192	9,694	6,383
64:00 Metal Antagonists	169	37,226	32,477
68:00 Hormones and Substitutes	1,161,902	30,311,627	15,007,928
84:00 Skin and Mucous Membrane Preparations	270,905	5,552,578	2,293,341
86:00 Spasmolytics	49,912	1,123,564	894,631
88:00 Vitamins	83,992	267,674	457,036
92:00 Unclassified and others	587,485	47,942,734	39,664,320
<b>Total</b>	<b>9,626,629</b>	<b>\$ 328,790,826</b>	<b>\$ 198,843,985</b>


1 The drug classification system used is that of the American Hospital Formulary Service

2 Refers to Formulary and Exception Drug Status drugs.

3 Includes Mark-up on drug acquisition cost.

Figure 2 shows the Table 7 prescription volume by Pharmacologic – Therapeutic Classification.

**Figure 2**  
**Prescription Volume by Pharmacologic - Therapeutic Classification**



## Pharmacies

A total of 374 pharmacies held agreements with Drug Plan & Extended Benefits Branch on March 31, 2006. Of these, 64.2% were independent pharmacies, 28.0% were chain outlets, and 5.1% were co-operatives.

**Table 8**  
**Pharmacies by Location**

April 2006 - March 2007

Location of Pharmacy	Number of Pharmacies <sup>1</sup>
Single Pharmacy Communities	91
2 - 5 Pharmacy Communities	65
Communities with More Than 5 Pharmacies	
Moose Jaw	13
North Battleford	7
Prince Albert	15
Regina	56
Saskatoon	77
Swift Current	7
Weyburn	7
Yorkton	7
Dispensing Doctors	7
Border Pharmacies	19
Hospital Outpatient	3
<b>Total</b>	<b>374</b>

1 Includes all pharmacies operating under agreement with the Prescription Drug Plan on March 31, 2007.

**Table 9**  
**Pharmacies by Type of Ownership**

Type of Ownership	Number of Pharmacies <sup>1</sup>	Percent
Independent	240	64.2%
Chain	105	28.0%
Co-operatives	19	5.1%
Dispensing Doctor	7	1.9%
Hospital Outpatient	3	0.8%
<b>Total</b>	<b>374</b>	<b>100.0%</b>

1 Includes all pharmacies operating under agreement with the Prescription Drug Plan on March 31, 2007.

## Manufacturers

Drug Acquisition Cost by manufacturer is presented in Table 10.

**Table 10**  
**Drug Acquisition Cost by Manufacturer**

April 2006 - March 2007

Manufacturer	Drug Acquisition Cost
3M Pharmaceuticals, 3M Canada .....	356,835.47
Abbott Laboratories Ltd. ....	4,285,072.61
Actelion Pharmaceutiques Canada .....	623,843.25
Alcon Canada Inc. ....	683,914.02
Allergan Inc. ....	1,147,261.04
Altana Pharma Inc. ....	1,661,232.33
Amgen Canada Inc. ....	4,887,575.17
Apotex Inc. ....	15,164,009.14
Astellas Pharma Canada Inc. ....	1,020,697.34
Astrazeneca .....	17,634,249.67
Autocontrol Medical .....	11,866.55
Axcan Pharma .....	760,595.70
Baker Cummins Inc. ....	1,283,931.05
Bayer Inc. - Consumer Care Division .....	17,883.76
Bayer Inc. - Healthcare Division .....	7,272,468.00
Becton-Dickinson Canada Inc. ....	940,110.90
Berlex Canada Inc. ....	2,840,464.52
Biogen Canada Inc. ....	988,707.07
Biovail Pharmaceuticals Canada.....	1,145,881.65
Boehringer Ingelheim (Can.) Ltd. ....	5,538,685.33
Bristol Pharmaceutical Products .....	86,297.57
Bristol-Myers Squibb Canada Co. ....	4,334,452.46
Canderm Pharma Inc. ....	9,567.29
Celgene Corporation .....	21,422.00
Chiron Canada Ltd. ....	137,522.08
Church & Dwight Canada .....	10,946.01
Cobalt Pharmaceutucals Inc. ....	380,810.71
Dermik Laboratories Canada Inc. ....	201,125.52
Dominion Pharmacal .....	333,343.79
Duchesnay Inc. ....	149,306.45
Eli Lilly Canada Inc. ....	7,289,351.50
Enzon Inc. ....	149,306.45
ERFA Canada Inc. ....	78,720.74
Ethypharm Inc. ....	22,708.10
Ferring Inc. ....	657,208.22

Manufacturer	Drug Acquisition Cost
Fournier Pharma Inc. ....	10,203.36
Galderma Canada Inc. ....	273,100.85
Genpharm Inc. ....	4,754,054.71
Genzyme Canada Inc. ....	407,526.72
Glaxosmithkline ....	15,267,350.38
Glaxosmithkline Consumer Health.....	208,589.98
Glenwood Laboratories Canada Ltd. ....	7,254.95
Hill Dermaceuticals, Inc. ....	17,525.39
Hoffman-La Roche Limited ....	4,182,877.20
Insight Pharmaceuticals Corp. ....	18,079.36
Jacobus Pharm Inc. ....	13,296.95
Janssen-Ortho Inc. ....	14,156,306.24
Key, Div. Of Schering Can. Inc. ....	1,067,403.46
Leo Pharma Inc. ....	772,381.41
LifeBrand (Shoppers Drug Mart) ....	8,692.03
Lifescan Canada Ltd. ....	4,446,580.41
Lundbeck Canada Inc. ....	466,130.41
Mayne Pharma (Canada) Inc. ....	333,188.37
McNeil Consumer HealthCare ....	24,106.10
Medicis Canada Ltd. ....	17,785.91
Medisense Products - Division of Abbott ....	1,052,827.41
Merck Frosst Canada Ltd. ....	16,312,338.54
Novartis Ophthalmics ....	71,754.19
Novartis Pharma Canada Inc. ....	10,715,428.21
Novo Nordisk Canada Inc. ....	2,567,376.69
Novopharm Ltd. ....	6,832,077.28
Nu-Pharm Inc. ....	15,015,029.83
Odan Laboratories Limited ....	120,222.21
Omega Laboratories Ltd. ....	37,729.66
Organon Canada Ltd. ....	1,237,129.49
Orphan Medical Inc. ....	20,305.98
ORYX Pharmaceuticals Inc. ....	6,691.51
Paladin Labs Inc. ....	542,378.06
Pendopharm Inc. ....	44,283.96
Pfizer Canada Inc. ....	38,054,957.69
Pfizer Canada-Consumer Health Care ....	19,108.67
Pharmascience Inc. ....	3,637,849.67
Pharmel Inc. ....	10,091.50
Prempharm Inc. ....	59,946.65
Procter & Gamble Pharm. Canada, Inc. ....	3,844,944.77
Purdue Pharma ....	4,089,433.63
Ratiopharm ....	3,852,293.50
Rhodiapharm ....	14,850.18
Rhoxalpharma Inc. ....	24,900.04
Roche Diagnostics, Hoffmann-LaRoche ....	2,051,513.93

Manufacturer	Drug Acquisition Cost
Sandoz Canada Inc. ....	1,315,791.42
Sanofi-Aventis .....	13,391,684.18
Schering Canada Inc. ....	9,001,295.97
Schircks Laboratories, Switzerland .....	7,948.64
Serono Canada Inc. ....	2,842,360.89
Servier Canada Inc. ....	2,027,659.38
Shire Biochem Inc. ....	372,923.62
Solvay Pharma Inc. ....	1,023,434.28
Squibb Pharmaceutical Products .....	29,216.49
Squire Pharmaceuticals Inc. ....	223,198.60
Sterimax Inc. ....	10,801.41
Stiefel Canada Inc. ....	318,193.03
Taro Pharmaceuticals Inc. ....	932,425.59
TaroPharma Inc. ....	83,946.93
Teva Neuroscience .....	4,329,615.71
Theramed Corporation .....	60,090.56
Tyco Healthcare .....	91,631.24
Ucyclid Pharma .....	126,383.78
Valeant Canada Limited .....	1,561,722.52
Virco Pharmaceuticals (Canada) Co. ....	533,982.44
Westwood Squibb Canada .....	56,602.67
Wyeth Pharmaceuticals .....	10,246,654.90
Extemporaneous Preparations <sup>1</sup> .....	1,071,149.17
Others (each under \$5000) .....	11,496,695.26
<b>Total</b> .....	<b>299,970,679.58</b>

<sup>1</sup> Extemporaneous Preparations are compounded by the pharmacist.



---

## *2006-2007 Utilization Trends*

### **1. Cost to Beneficiaries**

Trend information from Table 11 for the past four years shows that the number of active beneficiaries has remained fairly constant while the number of prescriptions and total prescription cost is increasing.

	<u>Active Beneficiaries</u>	<u>Number of Prescriptions</u>	<u>Total Cost of Prescriptions</u>	<u>Total Drug Plan Payment</u>
1995-96	633,333	5,798,090	\$157,194,207	\$ 59,492,033
1996-97	626,953	5,996,106	\$162,165,923	\$ 61,863,705
1997-98	620,258	6,261,167	\$171,208,698	\$ 65,199,190
1998-99	633,020	6,622,455	\$189,003,078	\$ 75,892,289
1999-00	633,259	7,014,580	\$204,982,067	\$ 85,368,696
2000-01	633,698	7,534,187	\$232,474,567	\$ 98,907,678
2001-02	629,090	7,979,826	\$261,413,126	\$114,865,694
2002-03	620,866	8,350,855	\$297,844,480	\$132,274,241
2003-04	623,914	8,641,855	\$327,787,913	\$149,163,934
2004-05	625,924	8,919,090	\$346,752,834	\$164,410,108
2005-06	638,637	9,364,871	\$375,304,926	\$181,288,493
2006-07	631,225	9,626,629	\$402,322,418	\$198,843,985

Table 11 was prepared to highlight three factors that might contribute to the increased growth: number of prescriptions per beneficiary; average prescription cost; and cost of prescriptions per beneficiary.

In Table 11, the total cost of prescriptions per active beneficiary has grown an average of 15.1% between 2004-05 and 2006-07 for all beneficiaries. The range of increases, based on age, was 5.5% to 15.9%.

The cost of prescriptions per beneficiary increased for all age groups; the average prescription cost increased for all age groups and the average number of prescriptions per beneficiary increased for all age groups with the exception of the 0 – 4 age group.

**Table 11**  
**Prescription Drug Utilization Trend by Age of Active Beneficiary**  
**Information Source: Table 2**

Age of Consumer	2004-05	2005-06	2006-07	% increase (decrease) 04-05 to 06-07
<b>April 1- March 31</b>				
<b>Average Number of Prescriptions Per Active Beneficiary</b>				
0 - 4	3.3	3.4	3.3	0.0%
5 - 14	3.6	3.7	3.7	2.0%
15 - 24	5.3	5.3	5.3	0.8%
25 - 34	7.0	7.1	7.1	2.1%
35 - 44	9.3	9.5	9.7	4.3%
45 - 54	13.5	13.9	14.2	5.2%
55 - 64	20.2	21.0	21.5	6.3%
65 - 74	27.1	28.1	28.9	6.7%
75 - 84	33.7	34.8	35.9	6.4%
85 and over	38.8	39.5	40.4	4.1%
<b>Total</b>	<b>14.2</b>	<b>14.7</b>	<b>15.3</b>	<b>7.7%</b>
<b>Average Prescription Cost <sup>1</sup></b>				
0 - 4	\$19.12	\$19.92	\$20.76	8.6%
5 - 14	33.35	33.46	34.66	3.9%
15 - 24	36.35	37.23	37.89	4.2%
25 - 34	40.27	42.15	43.03	6.9%
35 - 44	45.88	47.25	48.80	6.4%
45 - 54	44.45	46.03	48.29	8.6%
55 - 64	41.16	42.82	44.91	9.1%
65 - 74	38.52	39.59	41.72	8.3%
75 - 84	35.94	36.77	38.27	6.5%
85 and over	32.05	32.62	33.49	4.5%
<b>Total</b>	<b>\$38.88</b>	<b>\$40.08</b>	<b>\$41.79</b>	<b>7.5%</b>
<b>Total Cost of Prescriptions Per Active Beneficiary</b>				
0 - 4	\$63.18	\$67.52	\$68.04	7.7%
5 - 14	120.61	124.46	127.35	5.6%
15 - 24	191.80	196.58	202.41	5.5%
25 - 34	280.14	298.37	307.55	9.8%
35 - 44	425.25	447.45	473.27	11.3%
45 - 54	597.92	640.65	685.79	14.7%
55 - 64	831.84	898.20	964.46	15.9%
65 - 74	1,044.74	1,110.48	1,206.26	15.5%
75 - 84	1,211.43	1,278.14	1,372.65	13.3%
85 and over	1,243.96	1,287.35	1,352.39	8.7%
<b>Total</b>	<b>\$553.99</b>	<b>\$587.67</b>	<b>\$637.37</b>	<b>15.1%</b>

<sup>1</sup> Includes Drug Acquisition Cost, mark-up and dispensing fees paid to pharmacies.

---

## 2. Costs by Therapeutic Classification

Table 12 shows the cost of drugs covered by the Drug Plan by therapeutic classification.

During the three-year period from 2004-05 to 2006-07, the total cost of all prescriptions changed from a decrease of 1.7% to an increase of 22.1% for the following reasons:

- Autonomic Drugs increased the most due to a combination of a 12.5% increase in average prescription cost and an 8.6% increase in the number of prescriptions.
- The next greatest increase was for Cardiovascular Drugs due to a combination of a 13.8% increase in the number of prescriptions and a 7.3% increase in average prescription cost.
- The total prescription cost of Hormones and Substitutes increased by 18.4% as a result of a 12.7% increase in average prescription costs and a 5.1% increase in the number of prescriptions.
- Diagnostic Agents showed an increase of 14.7% as a result of a 11.2% increase in the number of prescriptions and an increase in average prescription cost of 3.2%.
- The total prescription cost of Anti-Infectives increased by 14.2% as a result of a 2.5% increase in the number of prescriptions and a 11.4% increase in the average prescription cost.
- Eye, Ear, Nose, and Throat Preparations showed an increase of 13.2% in total prescription cost as well as an increase of 10.9% in average prescription cost and a 2.1% increase in the number of prescriptions.
- Electrolytic, Caloric and Water Balance showed a 10.8% increase in total prescription cost and a 8.1% increase in average prescription and an increase of 2.5% in number of prescriptions.
- Gastrointestinal Drugs showed a 10.8% increase in total prescription cost and a 11.9% increase in the number of prescriptions while showing a 1.0% decrease in average prescription cost.
- Skin & Mucous Membrane Preparations decreased by 1.7% resulting from an increase of 0.6% in the number of prescriptions and a decrease of 2.3% in the average prescription cost
- Central Nervous System Drugs showed an increase of 6.5% due to a 3.3% increase in the number of prescriptions and a 3.0% increase in the average prescription cost.

**Table 12**  
**Prescription Trend by Pharmacologic - Therapeutic Classification**

Pharmacologic - Therapeutic Class	2004-05	2005-06	2006-07	% increase (decrease) 03-04 to 05-06
April 1 - March 31				
<b>Total Cost of all Prescriptions</b>				
Cardiovascular Drugs	\$ 107,309,800	\$ 118,470,820	130,967,262	22.0%
Central Nervous System Drugs	70,818,378	73,518,172	75,396,014	6.5%
Hormones and Substitutes	32,172,172	34,392,358	38,106,808	18.4%
Gastrointestinal Drugs	21,271,343	21,629,930	23,576,403	10.8%
Anti-Infectives	15,213,203	16,994,039	17,376,593	14.2%
Skin & Mucous Membrane Preparations	7,776,589	8,024,253	7,640,613	(1.7%)
Eye, Ear, Nose and Throat Preparations	9,065,145	9,966,434	10,257,512	13.2%
Autonomic Drugs	10,810,792	12,389,978	13,203,463	22.1%
Diagnostic Agents	9,892,566	10,701,397	11,350,078	14.7%
Electrolytic, Caloric, and Water Balance	6,159,877	6,464,028	6,823,235	10.8%
Others	56,262,968	62,753,518	67,624,437	20.2%
<b>Total</b>	<b>\$ 346,752,834</b>	<b>\$ 375,304,927</b>	<b>\$ 402,322,418</b>	<b>16.0%</b>
<b>Number of Prescriptions</b>				
Cardiovascular Drugs	2,558,227	2,736,693	2,910,071	13.8%
Central Nervous System Drugs	1,836,431	1,875,368	1,897,562	3.3%
Hormones and Substitutes	1,105,952	1,132,470	1,161,902	5.1%
Gastrointestinal Drugs	449,324	479,656	502,811	11.9%
Anti-Infectives	651,758	692,269	668,222	2.5%
Skin & Mucous Membrane Preparations	269,333	273,494	270,905	0.6%
Eye, Ear, Nose and Throat Preparations	292,675	306,854	298,745	2.1%
Autonomic Drugs	281,266	301,281	305,341	8.6%
Diagnostic Agents	120,039	129,339	133,490	11.2%
Electrolytic, Caloric, and Water Balance	516,287	525,307	529,127	2.5%
Others	837,798	912,140	948,453	13.2%
<b>Total</b>	<b>8,919,090</b>	<b>9,364,871</b>	<b>9,626,629</b>	<b>7.9%</b>
<b>Average Prescription Cost</b>				
Cardiovascular Drugs	\$ 41.95	\$ 43.29	\$ 45.00	7.3%
Central Nervous System Drugs	38.56	39.20	39.73	3.0%
Hormones and Substitutes	29.09	30.37	32.80	12.7%
Gastrointestinal Drugs	47.34	45.09	46.89	(1.0%)
Anti-Infectives	23.34	24.55	26.00	11.4%
Skin & Mucous Membrane Preparations	28.87	29.34	28.20	(2.3%)
Eye, Ear, Nose and Throat Preparations	30.97	32.48	34.34	10.9%
Autonomic Drugs	38.44	41.12	43.24	12.5%
Diagnostic Agents	82.41	82.74	85.03	3.2%
Electrolytic, Caloric, and Water Balance	11.93	12.31	12.90	8.1%
Others	67.16	68.80	71.30	6.2%
<b>Total</b>	<b>\$ 38.88</b>	<b>\$ 40.08</b>	<b>\$ 41.79</b>	<b>7.5%</b>

**Table 13**  
**Prescription Drug Plan Payments Summary**

**April 2006 - March 2007**

**Statistical Tables**

Payments on behalf of families (exempt from deductible program)	
Drug Material Acquisition Cost.....	\$ 43,392,763
Mark-up.....	3,820,422
Dispensing Fee Subsidy.....	8,085,226
Pharmacy Discounts and others.....	<u>(0)</u>
Total Payments for families exempt from deductible.....	\$ 55,298,410
Payments to or on behalf of families (deductible and Special Support program)	
Drug Material Acquisition Cost.....	\$256,578,040
Mark-up.....	24,999,602
Dispensing Fees.....	64,844,836
Pharmacy Discounts and others.....	<u>0</u>
Total Approved Prescription Cost.....	\$346,422,478
Less: Deductible Credits.....	<u>158,289,401</u>
	\$188,133,077
Less: Family Co-Payment.....	<u>44,587,502</u>
Total Payments for families subject to deductible.....	<u>\$ 143,545,575</u>
<b>Total Prescription Drug Plan Payments</b> <sup>1</sup> .....	\$ 198,843,985
Third Party payments/manual adjustments <sup>2</sup> .....	1,305,358
<b>Net Payments by MIDAS System</b> <sup>3</sup> .....	<u>\$ 200,149,343</u>

<sup>1</sup> Drug Plan payments refer to formulary drugs and exception status drugs. All Statistical Tables do not reflect manual adjustment expenditures.

<sup>2</sup> Third Party payments includes payments to RHA's for Visudyne and payments for Flolan. Manual adjustments include year-end adjustments made in accordance with accounting policies and other adjustments

<sup>3</sup> MIDAS is a central financial system.

---

# *Supplementary Health and Family Health Benefits*

## **BACKGROUND**

- On April 1, 1966 the Saskatchewan Assistance Plan was instituted. Several categories of beneficiaries under the Medical Services Division were combined into one program with the basis of need becoming the criteria to determine eligibility.
- On September 1, 1968 coverage for refractions was moved to the Saskatchewan Medical Care Insurance.
- On September 1, 1975 payment responsibility of formulary drugs and of prosthetic and orthotic appliances for Social Assistance beneficiaries was taken over by the Saskatchewan Prescription Drug Plan and by the Saskatchewan Aids to Independent Living respectively.
- On July 1, 1981 program eligibility was expanded to include benefits for non-recipients of Social Assistance receiving level 2, 3, and 4 Special Care Home or long term hospital care where incomes are at or below the Saskatchewan Income Plan level.
- On May 1, 1984 responsibility for emergency medical transportation costs by road ambulance and Saskatchewan Government air ambulance for Supplementary Health beneficiaries was transferred from the Department of Social Services.
- On June 1, 1992 eye examinations were added to coverage for Supplementary Health beneficiaries over the age of 17, and for adults receiving the Family Income Plan and the Saskatchewan Income Plan supplements.
- On September 8, 1992 services of chiropractors became fully covered for Supplementary Health, Family Income Plan and Saskatchewan Income Plan beneficiaries.
- On June 30, 1993 Supplementary Health began providing dental coverage for children in families that received the Family Income Plan supplement.
- On May 1, 1997 began providing all Supplementary Health Benefits for children in Family Income Plan families.
- On August 1, 1998 began providing Family Health Benefits for families who received the Saskatchewan Child Benefit and/or the Saskatchewan Employment Supplement. Family Income Plan recipients became part of Family Health Benefits.

---

## ***OBJECTIVES***

To provide for payment of accounts for non-insured health services to people nominated for coverage by the Department of Community Resources.


## ***ELIGIBLE BENEFICIARIES***

The Supplementary Health program provides benefits for the following types of beneficiaries:

- Supplementary Health beneficiaries:
  - Saskatchewan Assistance Plan recipients nominated by the Department of Community Resources.
  - Government Wards
  - Inmates of correctional institutions.
  - Nominated persons 65 years and older who are in special care homes or hospitals and whose income is at or below the Saskatchewan Income Plan level.
- The Family Health Benefits Program provides benefits for families with at least one child under the age of eighteen who may be receiving the Saskatchewan Child Benefit, the Saskatchewan Employment Supplement or the National Child Benefit.

---

### Supplementary Health Program



The above chart shows on average, 39,378 persons receiving full Supplementary Health benefits. Families receiving Family Health Benefits or SIP income supplements receive only partial Supplementary Health benefits and are not included in the numbers above.

During 2006-07, the average number of families eligible for Family Health Benefits was 19,295. This includes 24,915 adults and 33,715 children.




**Table 14**  
**Supplementary Health Program and Family Health Benefits Payments**

April 2006- March 2007

Services	Sask. Assistance Plan	Government Wards	Provincial Correctional Institutions	Sask. Income Plan Recipients in Special Care Homes	Family Health Benefits	Other Beneficiary Categories	Totals
Medical Examinations and Reports.....	\$ 292,661	\$ 5,189	\$ 340	\$ -	\$ 1,478	\$ 370	\$ 300,038
Dental Services.....	\$ 3,884,209	\$ 346,435	\$ 292,523	\$ 17,911	\$ 2,547,302	\$ 159,035	7,247,415
Non-Formulary Drugs (Plan 3).....	\$ 1,796,699	\$ 271,793	\$ 151,683	\$ 494,122	\$ 277	\$ 5,558	2,720,132
Medical Appliances and Supplies.....	\$ 720,268	\$ 48,092	\$ 2,612	\$ 70,960	\$ 113,956	\$ 8,575	964,463
Optical Services.....	\$ 1,028,087	\$ 81,435	\$ 66,871	\$ 8,976	\$ 631,556	\$ 159,426	1,976,351
Chiropractic Services.....	\$ 563,975	\$ 4,940	\$ 1,504	\$ 1,772	\$ 1,057,255	\$ 178,353	1,807,799
Ambulance.....	\$ 1,763,403	\$ 52,443	\$ 23,239	\$ 31,605	\$ 143,431	\$ 20,966	2,035,087
Medical Transportation (Aircraft).....	\$ 502,078	\$ -	\$ -	\$ -	\$ 8,173	\$ 10,131	520,382
Medical Transportation (Ground).....	\$ 1,850,683	\$ 20,603	\$ -	\$ -	\$ 57,382	\$ 32,105	1,960,773
<b>Totals: Supplementary Health and Family Health Benefits.....</b>	<b>\$ 12,402,063</b>	<b>\$ 830,930</b>	<b>\$ 538,772</b>	<b>\$ 625,346</b>	<b>\$ 4,560,810</b>	<b>\$ 574,519</b>	<b>\$ 19,532,440</b>


## 1. Medical Services

Supplementary Health and Family Health Benefits pays the cost for non-insured third party medical examinations and reports requested by the Department of Community Resources. These examinations are to determine the level of required nursing care, rehabilitation potential and employability.



## 2. Dental Services

Coverage includes preventive, restorative, exodontic, and prosthetic dentistry for eligible beneficiaries. Only children are eligible for Family Health Benefits coverage.




---

### 3. Non-Formulary Drug Benefits

Supplementary Health provides certain non-Formulary drugs without charge for Plan Three residents in nursing and approved community homes, government wards and provincial correctional centre inmates. Formulary and non-Formulary drug benefits for the different levels of Social Assistance Plan coverage are outlined earlier in the report on page 9.

Coverage may also be granted in unusual circumstances for Plan One and Two beneficiaries where drug requirements are not met by Formulary drugs or products approved under Exception Drug Status.




---

#### 4. Medical Supplies and Appliances

Supplementary Health and Family Health Benefits covers the full cost of most medical supplies and appliances prescribed by a physician for covered beneficiaries.

**Medical Supplies and Appliances**




---

## 5. Optometric Services


Eyeglasses are covered for Supplementary Health beneficiaries and children of families approved for Family Health Benefits, whether provided by an optometrist or ophthalmic dispensary. Payment is made on the basis of laboratory costs plus a dispensing fee. Fees are paid according to negotiated payment schedules. There is an upper limit on the amount paid for eyeglass frames.

The cost of eye examinations is covered for all Supplementary Health beneficiaries age 18 and over. Children are covered on a universal basis by the Medical Services Branch.




## 6. Chiropractic Services

The services of chiropractors are fully covered for Supplementary Health, Family Health Benefits and Saskatchewan Income Plan beneficiaries.



## 7. Medical Transportation – Ambulance

Benefits include coverage for emergency medical transportation by road ambulance.



---

## **8. Medical Transportation – Northern Medical Transportation Program**

This Program supports:

- emergency medical evacuation from sites in the North for Saskatchewan residents; and
- non-emergent medical transportation for Supplementary Health beneficiaries and Family Health Benefits children, residing in the North.

During 2006-07 the costs of the medical transportation for the Northern Medical Transportation Program was \$2.5 million.

---

# *Saskatchewan Aids to Independent Living (SAIL)*

## **BACKGROUND**

- SAIL began providing benefits on April 1, 1975, to eligible residents for prosthetic/orthotic devices.
- On August 1, 1975 SAIL benefits expanded to provide equipment loans and equipment repairs for all residents of the province.
- On April 1, 1976 SAIL took over responsibility for: the Paraplegia Program which covers the cost of appliances recommended by the attending physician; the Cystic Fibrosis Program which provides drugs and special appliances for certain beneficiaries; and the Chronic End Stage Renal Disease Program which provides assistance with the cost of necessary medications for certain beneficiaries.
- In 1979-80 the Ostomy and Home Hemophilia programs were added.
- In 1984-85 coverage expanded to include aids and services required by the blind residents in the province.
- In June 1987 the responsibility for the acquisition, distribution and repair of Special Needs Equipment (eg. wheelchairs, patient lifts, etc.) was transferred to the Saskatchewan Abilities Council. SAIL continues to fund the full cost of the program.
- In August 1987 took over administration of the Home Oxygen Program from the Drug Plan.
- In September 1987 responsibility for the acquisition, distribution and repair of equipment required by the blind was transferred to the Canadian National Institute for the Blind (CNIB). SAIL continues to provide funding to CNIB for delivery of these services.
- In 1996-97 benefits under the Home Oxygen program were granted according to certain medical criteria.
- In 2003-04 the Nutritional Products program was added to assist with the incremental cost associated with using nutritional products in place of a regular diet.



## ***ELIGIBLE BENEFICIARIES***

People with long term disabilities or illnesses which leave them unable to function fully may receive specialized benefits through the SAIL program to help them achieve more independent and active lifestyles.

All Saskatchewan residents, with certain exceptions, are eligible for the universal benefits of Orthopaedic Services, Special Needs Equipment, Home Respiratory Services, Nutritional Products, Home Oxygen, and the Children's Enteral Feeding Pump Program.

Beneficiaries with particular disabling conditions are eligible under the various Special Benefit Programs; Paraplegia, Cystic Fibrosis, End Stage Renal Disease, Ostomy, Aids to the Blind and Haemophilia.

## ***PROGRAM OBJECTIVES***

SAIL has been established to provide aids and services to the physically disabled residents of Saskatchewan.

**Table 15**  
**Caseloads and SAIL Payments**

	2005-06		2006-07	
	Caseload	Expenditures	Caseload	Expenditures
Orthopaedic Services.....	5,907	\$2,501,134	6,256	\$3,429,027
Special Needs Equipment.....	n.a.	\$3,708,359	n.a.	\$3,738,007
Home Oxygen.....	2,590	\$9,061,108	2,606	\$8,937,927
Respiratory Equipment.....	n.a.	\$916,084	n.a.	\$1,118,646
Paraplegia.....	1,775	\$4,111,819	1,737	\$4,026,725
Cystic Fibrosis.....	109	\$206,265	113	\$183,958
Renal Disease.....	923	\$3,707,628	981	\$4,258,209
Ostomy.....	2,038	\$939,295	2,088	\$1,009,311
Aids to the Blind.....	n.a.	\$298,176	n.a.	\$343,482
Other Payments	n.a.	\$262,342	n.a.	\$313,304
<b>Total</b>		<b>\$25,712,210</b>		<b>\$27,358,596</b>

**NOTE: n.a. is not available**

---


## 1. Orthopaedic Services

**Prosthetic Appliances** – Artificial limbs and accessories are supplied, fitted, adjusted and repaired without charge.

**Orthotic Appliances** – Higher-cost back braces, knee braces and splints are supplied, fitted, adjusted, and repaired without charge.

Specialized and adaptive seating, and custom-built footwear are also provided by SAIL. All of the above services are supplied by the orthotics and prosthetics departments of the Wascana Rehabilitation Centre in Regina and the Saskatchewan Abilities Council in Saskatoon.

Custom pressure or burn garments are supplied and fitted without charge. SAIL arranges for the supplier to provide garments.




---

## 1. Special Needs Equipment

**Mobility Aids** – Wheelchairs, walkers, and specialized crutches are loaned, maintained and repaired without charge. Eligibility is assessed based on long-term need.

**Environmental Aids** – Higher-cost equipment such as hospital beds and accessories, transfer assists and commodes are loaned, maintained and repaired without charge. Eligibility is assessed based on long-term need.



The Special Needs Equipment Program is operated by the Saskatchewan Abilities Council under contract with SAIL. Equipment depots are located in Prince Albert, Regina, Saskatoon, Swift Current and Yorkton.



### 3. Home Respiratory Services

**Home Oxygen Therapy** – Home oxygen and related equipment are benefits under SAIL for Saskatchewan residents who meet medical criteria. The systems are supplied by private medical oxygen supply firms under contract with SAIL.

**Respiratory Equipment** – SAIL shares the purchase cost of aerosol therapy compressors for eligible beneficiaries, who are responsible for maintenance and repairs. Home respiratory equipment such as ventilators, continuous positive airway pressure (CPAP) units, suction pumps, and tracheostomy humidification packs are loaned, maintained and repaired without charge. Eligibility is based on specific medical criteria.



---

## 4. Nutritional Products

The program assists with the cost of specialized nutritional products for persons with complex medical conditions who rely on those products as their primary nutritional source. Program benefits are cost shared between clients and Saskatchewan Health, with the patient's portion varying based on a number of factors, including family income.

The program commenced September 1, 2003. During 2006-07, 79 clients were receiving benefits with expenditures totaling almost \$112,000.

## 5. Special Benefit Programs

In addition to regular SAIL Program benefits, extended coverage is provided to beneficiaries with particular disabling conditions.

**Paraplegia Program** – Drugs listed in the Saskatchewan Formulary, drugs approved for coverage under the Drug Plan Exception Drug Status program as well as certain non-Formulary drugs are available at no charge. Incontinence management and dressing supplies for chronic conditions are available without charge. Specialized rehabilitation equipment is loaned, maintained and repaired without charge. Financial assistance is also provided for vehicle hand controls, ramps and wheelchair lifts.

**Cystic Fibrosis Program** – Drugs listed in the Saskatchewan Formulary, drugs approved for coverage under the Drug Plan Exception Drug Status program as well as certain non-Formulary drugs are available at no charge. In addition, certain food supplements and digestants are covered.

**End Stage Renal Disease Program** – Drugs listed in the Saskatchewan Formulary, drugs approved for coverage under the Drug Plan Exception Drug Status program as well as certain non-Formulary drugs are available at no charge to persons with end-stage renal disease or renal transplant recipients.


**Ostomy Program** – SAIL provides 50% reimbursement of certain ostomy supplies, such as appliances, adhesives and adhesive removers, to eligible persons referred by enterostomal therapists.

**Aids to the Blind Program** – Financial assistance is provided for aids such as braille watches, talking calculators and low-vision eyewear. Braillers, talking book machines, tape players and recorders are loaned, maintained and repaired without charge. Magnifiers and telescopes are supplied without charge. Low vision eyewear is provided through optometric/ophthalmic dispensers. Equipment services are provided by the Canadian National Institute for the Blind (CNIB) under contract with SAIL.

**Haemophilia Program** – The Haemophilia Program covers the total cost of medical supplies associated with home infusion for the treatment of haemophilia.


**Children’s Enteral Feeding Pump Program** – Feeding pumps are provided by SAIL on a free loan basis to children who require nasogastric or gastrostomy pump feeding. Select consumable supplies associated with pump feeding are also a benefit.

**Special Benefit Programs**



Note: The Special Benefits Programs charts show only the number of caseloads and program expenditures for Paraplegia, Cystic Fibrosis and Renal Disease.

**Special Benefit Programs**



**Table 16**  
**Special Needs Equipment Program - Loans**

April 1- March 31	2003-04	2004-05	2005-06	2006-07
Wheelchairs				
- Manual.....	4,303	4,028	3,788	3,564
- Power (electric).....	137	124	150	124
Other Aids.....	17,131	16,801	18,986	19,741
<b>Total Loans</b>	<b>21,571</b>	<b>20,953</b>	<b>22,924</b>	<b>23,429</b>

**Table 17**  
**Orthopaedic Services - Appliances Issued**

April 1- March 31	2003-04	2004-05	2005-06	2006-07
Prosthetics.....	164	146	161	170
Orthotics.....	2,989	2,938	2,746	2,507
Footwear (braced).....	89	106	124	105
Adaptive and Specialized Seating for Wheelchairs.....	1,403	1,446	1,545	1,436
<b>Total Issues</b>	<b>4,645</b>	<b>4,636</b>	<b>4,576</b>	<b>4,218</b>

**Table 18**  
**Orthopaedic Services - Appliances Repaired**

April 1- March 31	2003-04	2004-05	2005-06	2006-07
Prosthetics.....	1,219	1,110	1,146	1,113
Orthotics.....	1,345	1,322	1,441	1,802
Footwear (braced).....	92	78	95	105
Adaptive and Specialized Seating for Wheelchairs.....	544	558	436	548
<b>Total Repairs</b>	<b>3,200</b>	<b>3,068</b>	<b>3,118</b>	<b>3,568</b>